Capricor Therapeutics completes enrollment of phase II clinical trial for cenderitide
Capricor announced it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications. March 31, 2015